China’s first inactivated vaccine developed by China National Biotec Group has entered Phase II clinical trials.
According to Global Times on Friday, the 96 volunteers who received the vaccine in Phase I trials are in good condition.
China begun the second phase of clinical trials for a COVID-19 vaccine with 500 volunteer participants recruited from Wuhan, the initial epicenter of the outbreak, according to state media.
#China’s first inactivated vaccine, developed by China National Biotec Group, has entered Phase II clinical trials. The 96 volunteers who received the vaccine in Phase I trials are in good condition. #COVID19 pic.twitter.com/IBlEqzkGhy— Global Times (@globaltimesnews) April 24, 2020
It is the first Phase 2 human test for a COVID-19 vaccine in the global race to find a cure for the pandemic, the official Xinhua News Agency said recently.
According to Voice of America, China completed its Phase 1 trial at the end of March with 108 volunteers. All of them reportedly have been released from medical observation and are in good health.
While the first phase focused on the vaccine’s safety, the second phase inoculates many more people to determine how effective it is in protecting against infection.